Aileron Therapeutics Announces a 1-for-20 Reverse Stock Split
November 10, 2022 08:00 ET
|
Aileron Therapeutics, Inc.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 01, 2022 08:15 ET
|
Aileron Therapeutics, Inc.
Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023Presented healthy volunteer study...
Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
October 26, 2022 06:05 ET
|
Aileron Therapeutics, Inc.
p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair...
Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
September 30, 2022 08:41 ET
|
Aileron Therapeutics, Inc.
New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cellsEncore presentation of data presented at Society for Investigative Dermatology in...
Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference
September 22, 2022 08:00 ET
|
Aileron Therapeutics, Inc.
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 07:00 ET
|
Aileron Therapeutics, Inc.
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 15, 2022 16:15 ET
|
Aileron Therapeutics, Inc.
Company continues to advance ALRN-6924 as a selective chemoprotective agent for all patients with p53-mutated cancer, with immediate focus on breast cancer clinical trialExtended cash runway expected...
Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer
August 01, 2022 07:51 ET
|
Aileron Therapeutics, Inc.
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and...
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2022
July 08, 2022 08:31 ET
|
Aileron Therapeutics, Inc.
BOSTON, July 08, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more...
Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer
June 29, 2022 06:30 ET
|
Aileron Therapeutics, Inc.
Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between...